Aberrations and Therapeutics Involving the Developmental Pathway Hedgehog in Pancreatic cancer

Vitamins and Hormones

Volumn 88, Issue , 2012, Pages 355-378

  Kelleher, Fergal C ^a,b   McDermott, Raymond ^a,c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Desmoplasia; GDC 0449; Hedgehog; Ligand; Pancreatic cancer; Paracrine; Patched; Smoothened; Stroma

Indexed keywords

EID: 84857716118     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394622-5.00016-X     Document Type: Chapter

References (48)

1. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14(19):5995-6600.
2. Bailey J.M., Mohr A.M., Hollingsworth M.A. Sonic hedgehog paracrine signalling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009, 28(40):3513-3525.
3. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425(6960):846-851.
4. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Takeuchi K., Hamada T., Haruta H., Ishikawa Y., Kimura H., Mitsudomi T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363:1734-1739.
5. Dellovade T., Romer J.T., Curran T., Rubin L.L. The hedgehog pathway and neurological disorders. Annu. Rev. Neurosci. 2006, 29:539-563.
6. Developmental genetics and birth defects. Chapter 14, P441. Genetics in medicine. Thompson and Thompson, ISBN 9781416030805.
7. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., Trussell C., Schmitt-Graeff A., Landwerlin K., Veelken H., Warmuth M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14(3):238-249.
8. Evangelista M., Tian H., de Sauvage F.J. The hedgehog signaling pathway in cancer. Clin. Cancer Res. 2006, 12(20):5924-5928.
9. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K.L., Matsui W., et al. Blockade of hedgehog signalling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67(5):2187-2196.
10. Feldmann G., Habbe N., Dhara S., Bisht S., Alvarez H., Fendrich V. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57(10):1420-1430.
11. Garber K. Stromal depletion goes on trial in pancreatic cancer. J. Natl. Cancer Inst. 2010, 102(7):448-450. Cited abstract (2009) J. Clin. Oncol.27,15s (suppl; abstr 4525).
12. García de Marcos J.A., Dean-Ferrer A., Arroyo Rodríguez S., Calderón-Polanco J., Alamillos Granados F.J., Poblet E. Basal cell nevus syndrome: Clinical and genetic diagnosis. Oral Maxillofac. Surg. 2009, 13(4):225-230.
13. Hawes R.H., Xiong Q., Waxman I., Chang K.J., Evans D.B., Abbruzzese J.L. A multispeciality approach to approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 2000, 95:17-31.
14. Hedgehog signalling in human disease. Molecular biology intelligence unit. Ariel Ruiz i Altaba. Chapter 1, p2.
15. Heiser P.W., Lau J., Taketo M.M., Herrera P.L., Hebrok M. Stabilization of beta-catenin impacts pancreas growth. Development 2006, 133(10):2023-2032.
16. Heller R.S., Dichmann D.S., Jensen J., Miller C., Wong G., Madsen O.D., Serup P. Expression patterns of Wnts, Frizzleds, sFRPs, and misexpression in transgenic mice suggesting a role for Wnts in pancreas and foregut pattern formation. Dev. Dyn. 2002, 225(3):260-270.
17. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-323.
18. Ji Z., Mei F.C., Xie J., Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 2007, 282(19):14048-14055.
19. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
20. Kelleher F.C., et al. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006, 45(4):375-388.
21. Kimura H., Ng J.M., Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008, 13(3):249-260.
22. Krzyanowska M.K., Weeks J.C., Earle C.C. Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness. J. Clin. Oncol. 2003, 21(18):3409-3414.
23. Lauth M., Bergström A., Shimokawa T., Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA 2007, 104(20):8455-8460.
24. Lauth M., Bergström A., Shimokawa T., Tostar U., Jin Q., Fendrich V., Guerra C., Barbacid M., Toftgård R. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat. Struct. Mol. Biol. 2010, 17(6):718-725.
25. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
26. Martin R.C., Scoggins C.R., Egnatashvili V., Staley C.A., McMasters K.M., Kooby D.A. Arterial and venous resection for pancreatic adenocarcinoma: Operative and long-term outcomes. Arch. Surg. 2009, 144(2):154-159.
27. Merchant A.A., Matsui W. Targeting hedgehog-A cancer stem cell pathway. Clin. Cancer Res. 2010, 16(12):3130-3150.
28. Mimeault M., Moore E., Moniaux N., Hénichart J.P., Depreux P., Lin M.F., Batra S.K. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signalling inhibitors, in prostate cancer cells. Int. J. Cancer 2006, 118(4):1022-1031.
29. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960.
30. Morton J.P., Mongeau M.E., Klimstra D.S., Morris J.P., Lee Y.C., Kawaguchi Y., et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc. Natl. Acad. Sci. USA 2007, 104(12):5103-5108.
31. Nakamura K., Sasajima J., Mizukami Y., Sugiyama Y., Yamazaki M., Fujii R., Kawamoto T., Koizumi K., Sato K., Fujiya M., Sasaki K., Tanno S., et al. Hedgehog promotes neovascularisation in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One 2010, 5(1):e8824.
32. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007, 297(3):267-277.
33. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., et al. Inhibition of Hedgehog signalling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
34. Pasca di Magliano M., Biankin A.V., Heiser P.W., Cano D.A., Gutierrez P.J., Deramaudt T., Segara D., Dawson A.C., Kench J.G., Henshall S.M., Sutherland R.L., Dlugosz A., et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007, 2(11):e1155.
35. Riobó N.A., Lu K., Ai X., Haines G.M., Emerson C.P. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signalling. Proc. Natl. Acad. Sci. USA 2006, 103(12):4505-4510.
36. Romer J.T., Kimura H., Magdaleno S., Sasai K., Fuller C., Baines H., Connelly M., Stewart C.F., Gould S., Rubin L.L., Curran T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004, 6(3):229-240.
37. Rubin L.L., de Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006, 5(12):1026-1033.
38. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., LoRusso P.M., Von Hoff D.D., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 2009, 361(12):1173-1178.
39. Siu L.L., Papadopoulos K.P., Alberts S.R., Taylor S., Patnaik A., Chen E.X., et al. A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. Mol. Cancer Ther. 2009, 8:A55. Abstract. 10.1158/1535-7163.TARG-09-A55.
40. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Eng. J. Med. 2006, 354:2531-2541.
41. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernández-del Castillo C., Yajnik V., Antoniu B., McMahon M., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425(6960):851-856.
42. Tian H., Callahan C.A., DuPree K.J., Darbonne W.C., Ahn C.P., Scales S.J., de Sauvage F.J. Hedgehog signalling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA 2009, 106(11):4254-4259.
43. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Mackey H.M., Lum B.L., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009, 361(12):1164-1172.
44. Walter K., Omura N., Hong S.M., Griffith M., Vincent A., Borges M., Goggins M. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin. Cancer Res. 2010, 16(6):1781-1789.
45. Willett C.G., Czito B.G., Bendell J.C., Ryan D.P. J. Clin. Oncol. 2005, 23(20):4538-4544.
46. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455(7211):406-410.
47. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., Bazan J.F., Kan Z., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326(5952):572-574.
48. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8(10):806-823.